Cite
HARVARD Citation
King, H. et al. (2022). Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years. Archives of disease in childhood. 107 (2), pp. 205-207. [Online].